Report Detail
Global Glomerulonephritis Treatment Market Insights, Forecast to 2025
- RnM2997111 |
- 22 February, 2019 |
- Global |
- 120 Pages |
- QYResearch |
- Pharma & Healthcare
The global Glomerulonephritis Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Glomerulonephritis Treatment market based on company, product type, end user and key regions.
This report studies the global market size of Glomerulonephritis Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Glomerulonephritis Treatment in these regions.
This research report categorizes the global Glomerulonephritis Treatment market by top players/brands, region, type and end user. This report also studies the global Glomerulonephritis Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Achillion Pharmaceuticals Inc
Anthera Pharmaceuticals Inc
Biogen Inc
Bristol-Myers Squibb Company
Cellmid Ltd
ChemoCentryx Inc
Complexa Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline Plc
Merck KGaA
Omeros Corp
Pfizer Inc
Pharmalink AB
Ra Pharmaceuticals Inc
Retrophin Inc
Rigel Pharmaceuticals Inc
Shire Plc
Visterra Inc
Market size by Product
ACH-5228
AMY-101
Atacicept
Avacopan
AVX-002
Market size by End User
Home Care
Clinic
Hospital
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Glomerulonephritis Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Glomerulonephritis Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Glomerulonephritis Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Glomerulonephritis Treatment submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Glomerulonephritis Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Glomerulonephritis Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Glomerulonephritis Treatment Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Glomerulonephritis Treatment Market Size Growth Rate by Product
- 1.4.2 ACH-5228
- 1.4.3 AMY-101
- 1.4.4 Atacicept
- 1.4.5 Avacopan
- 1.4.6 AVX-002
- 1.5 Market by End User
- 1.5.1 Global Glomerulonephritis Treatment Market Size Growth Rate by End User
- 1.5.2 Home Care
- 1.5.3 Clinic
- 1.5.4 Hospital
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Glomerulonephritis Treatment Market Size
- 2.1.1 Global Glomerulonephritis Treatment Revenue 2014-2025
- 2.1.2 Global Glomerulonephritis Treatment Sales 2014-2025
- 2.2 Glomerulonephritis Treatment Growth Rate by Regions
- 2.2.1 Global Glomerulonephritis Treatment Sales by Regions
- 2.2.2 Global Glomerulonephritis Treatment Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Glomerulonephritis Treatment Sales by Manufacturers
- 3.1.1 Glomerulonephritis Treatment Sales by Manufacturers
- 3.1.2 Glomerulonephritis Treatment Sales Market Share by Manufacturers
- 3.1.3 Global Glomerulonephritis Treatment Market Concentration Ratio (CR5 and HHI)
- 3.2 Glomerulonephritis Treatment Revenue by Manufacturers
- 3.2.1 Glomerulonephritis Treatment Revenue by Manufacturers (2014-2019)
- 3.2.2 Glomerulonephritis Treatment Revenue Share by Manufacturers (2014-2019)
- 3.3 Glomerulonephritis Treatment Price by Manufacturers
- 3.4 Glomerulonephritis Treatment Manufacturing Base Distribution, Product Types
- 3.4.1 Glomerulonephritis Treatment Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Glomerulonephritis Treatment Product Type
- 3.4.3 Date of International Manufacturers Enter into Glomerulonephritis Treatment Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Glomerulonephritis Treatment Sales by Product
- 4.2 Global Glomerulonephritis Treatment Revenue by Product
- 4.3 Glomerulonephritis Treatment Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Glomerulonephritis Treatment Breakdown Data by End User
6 North America
- 6.1 North America Glomerulonephritis Treatment by Countries
- 6.1.1 North America Glomerulonephritis Treatment Sales by Countries
- 6.1.2 North America Glomerulonephritis Treatment Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Glomerulonephritis Treatment by Product
- 6.3 North America Glomerulonephritis Treatment by End User
7 Europe
- 7.1 Europe Glomerulonephritis Treatment by Countries
- 7.1.1 Europe Glomerulonephritis Treatment Sales by Countries
- 7.1.2 Europe Glomerulonephritis Treatment Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Glomerulonephritis Treatment by Product
- 7.3 Europe Glomerulonephritis Treatment by End User
8 Asia Pacific
- 8.1 Asia Pacific Glomerulonephritis Treatment by Countries
- 8.1.1 Asia Pacific Glomerulonephritis Treatment Sales by Countries
- 8.1.2 Asia Pacific Glomerulonephritis Treatment Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Glomerulonephritis Treatment by Product
- 8.3 Asia Pacific Glomerulonephritis Treatment by End User
9 Central & South America
- 9.1 Central & South America Glomerulonephritis Treatment by Countries
- 9.1.1 Central & South America Glomerulonephritis Treatment Sales by Countries
- 9.1.2 Central & South America Glomerulonephritis Treatment Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Glomerulonephritis Treatment by Product
- 9.3 Central & South America Glomerulonephritis Treatment by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Glomerulonephritis Treatment by Countries
- 10.1.1 Middle East and Africa Glomerulonephritis Treatment Sales by Countries
- 10.1.2 Middle East and Africa Glomerulonephritis Treatment Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Glomerulonephritis Treatment by Product
- 10.3 Middle East and Africa Glomerulonephritis Treatment by End User
11 Company Profiles
- 11.1 Achillion Pharmaceuticals Inc
- 11.1.1 Achillion Pharmaceuticals Inc Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Products Offered
- 11.1.5 Achillion Pharmaceuticals Inc Recent Development
- 11.2 Anthera Pharmaceuticals Inc
- 11.2.1 Anthera Pharmaceuticals Inc Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Products Offered
- 11.2.5 Anthera Pharmaceuticals Inc Recent Development
- 11.3 Biogen Inc
- 11.3.1 Biogen Inc Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Biogen Inc Glomerulonephritis Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Biogen Inc Glomerulonephritis Treatment Products Offered
- 11.3.5 Biogen Inc Recent Development
- 11.4 Bristol-Myers Squibb Company
- 11.4.1 Bristol-Myers Squibb Company Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Bristol-Myers Squibb Company Glomerulonephritis Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Bristol-Myers Squibb Company Glomerulonephritis Treatment Products Offered
- 11.4.5 Bristol-Myers Squibb Company Recent Development
- 11.5 Cellmid Ltd
- 11.5.1 Cellmid Ltd Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Cellmid Ltd Glomerulonephritis Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Cellmid Ltd Glomerulonephritis Treatment Products Offered
- 11.5.5 Cellmid Ltd Recent Development
- 11.6 ChemoCentryx Inc
- 11.6.1 ChemoCentryx Inc Company Details
- 11.6.2 Company Business Overview
- 11.6.3 ChemoCentryx Inc Glomerulonephritis Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 ChemoCentryx Inc Glomerulonephritis Treatment Products Offered
- 11.6.5 ChemoCentryx Inc Recent Development
- 11.7 Complexa Inc
- 11.7.1 Complexa Inc Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Complexa Inc Glomerulonephritis Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Complexa Inc Glomerulonephritis Treatment Products Offered
- 11.7.5 Complexa Inc Recent Development
- 11.8 Dimerix Bioscience Pty Ltd
- 11.8.1 Dimerix Bioscience Pty Ltd Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Products Offered
- 11.8.5 Dimerix Bioscience Pty Ltd Recent Development
- 11.9 GlaxoSmithKline Plc
- 11.9.1 GlaxoSmithKline Plc Company Details
- 11.9.2 Company Business Overview
- 11.9.3 GlaxoSmithKline Plc Glomerulonephritis Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 GlaxoSmithKline Plc Glomerulonephritis Treatment Products Offered
- 11.9.5 GlaxoSmithKline Plc Recent Development
- 11.10 Merck KGaA
- 11.10.1 Merck KGaA Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Merck KGaA Glomerulonephritis Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Merck KGaA Glomerulonephritis Treatment Products Offered
- 11.10.5 Merck KGaA Recent Development
- 11.11 Omeros Corp
- 11.12 Pfizer Inc
- 11.13 Pharmalink AB
- 11.14 Ra Pharmaceuticals Inc
- 11.15 Retrophin Inc
- 11.16 Rigel Pharmaceuticals Inc
- 11.17 Shire Plc
- 11.18 Visterra Inc
12 Future Forecast
- 12.1 Glomerulonephritis Treatment Market Forecast by Regions
- 12.1.1 Global Glomerulonephritis Treatment Sales Forecast by Regions 2019-2025
- 12.1.2 Global Glomerulonephritis Treatment Revenue Forecast by Regions 2019-2025
- 12.2 Glomerulonephritis Treatment Market Forecast by Product
- 12.2.1 Global Glomerulonephritis Treatment Sales Forecast by Product 2019-2025
- 12.2.2 Global Glomerulonephritis Treatment Revenue Forecast by Product 2019-2025
- 12.3 Glomerulonephritis Treatment Market Forecast by End User
- 12.4 North America Glomerulonephritis Treatment Forecast
- 12.5 Europe Glomerulonephritis Treatment Forecast
- 12.6 Asia Pacific Glomerulonephritis Treatment Forecast
- 12.7 Central & South America Glomerulonephritis Treatment Forecast
- 12.8 Middle East and Africa Glomerulonephritis Treatment Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Glomerulonephritis Treatment Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Glomerulonephritis Treatment . Industry analysis & Market Report on Glomerulonephritis Treatment is a syndicated market report, published as Global Glomerulonephritis Treatment Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Glomerulonephritis Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
